Literature DB >> 15143182

Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells.

Shelby O'Connor1, Stuart D Shumway, Ian J Amanna, Colleen E Hayes, Shigeki Miyamoto.   

Abstract

Constitutive NF-kappaB activity has emerged as an important cell survival component of physiological and pathological processes, including B-cell development. In B cells, constitutive NF-kappaB activity includes p50/c-Rel and p52/RelB heterodimers, both of which are critical for proper B-cell development. We previously reported that WEHI-231 B cells maintain constitutive p50/c-Rel activity via selective degradation of IkappaBalpha that is mediated by a proteasome inhibitor-resistant, now termed PIR, pathway. Here, we examined the mechanisms of PIR degradation by comparing it to the canonical pathway that involves IkappaB kinase-dependent phosphorylation and beta-TrCP-dependent ubiquitylation of the N-terminal signal response domain of IkappaBalpha. We found a distinct consensus sequence within this domain of IkappaBalpha for PIR degradation. Chimeric analyses of IkappaBalpha and IkappaBbeta further revealed that the ankyrin repeats of IkappaBalpha, but not IkappaBbeta, contained information necessary for PIR degradation, thereby explaining IkappaBalpha selectivity for the PIR pathway. Moreover, we found that PIR degradation of IkappaBalpha and constitutive p50/c-Rel activity in primary murine B cells were maintained in a manner different from B-cell-activating-factor-dependent p52/RelB regulation. Thus, our findings suggest that nonconventional PIR degradation of IkappaBalpha may play a physiological role in the development of B cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143182      PMCID: PMC416427          DOI: 10.1128/MCB.24.11.4895-4908.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  73 in total

1.  IkappaB is a substrate for a selective pathway of lysosomal proteolysis.

Authors:  A M Cuervo; W Hu; B Lim; J F Dice
Journal:  Mol Biol Cell       Date:  1998-08       Impact factor: 4.138

2.  Structure of an IkappaBalpha/NF-kappaB complex.

Authors:  M D Jacobs; S C Harrison
Journal:  Cell       Date:  1998-12-11       Impact factor: 41.582

3.  Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice.

Authors:  V M Lentz; C E Hayes; M P Cancro
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

Review 4.  B cell maturation and selection at the marrow-periphery interface.

Authors:  M P Cancro; D M Allman; C E Hayes; V M Lentz; R G Fields; A P Sah; M Tomayko
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  Signal-dependent and -independent degradation of free and NF-kappa B-bound IkappaBalpha.

Authors:  M P Pando; I M Verma
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

6.  Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53.

Authors:  F G Wulczyn; D Krappmann; C Scheidereit
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

7.  Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases.

Authors:  R Geleziunas; S Ferrell; X Lin; Y Mu; E T Cunningham; M Grant; M A Connelly; J E Hambor; K B Marcu; W C Greene
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate.

Authors:  E Zandi; Y Chen; M Karin
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

9.  Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation.

Authors:  Y Han; S Weinman; I Boldogh; R K Walker; A R Brasier
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

10.  Identification of the receptor component of the IkappaBalpha-ubiquitin ligase.

Authors:  A Yaron; A Hatzubai; M Davis; I Lavon; S Amit; A M Manning; J S Andersen; M Mann; F Mercurio; Y Ben-Neriah
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

View more
  14 in total

1.  MAGUK-controlled ubiquitination of CARMA1 modulates lymphocyte NF-kappaB activity.

Authors:  Miguel E Moreno-García; Karen Sommer; Hisaaki Shinohara; Ashok D Bandaranayake; Tomohiro Kurosaki; David J Rawlings
Journal:  Mol Cell Biol       Date:  2009-12-14       Impact factor: 4.272

2.  Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.

Authors:  Mailee Huynh; Chorom Pak; Stephanie Markovina; Natalie S Callander; Kenneth S Chng; Shelly M Wuerzberger-Davis; Debayan D Bakshi; John A Kink; Peiman Hematti; Chelsea Hope; Fotis Asimakopoulos; Lixin Rui; Shigeki Miyamoto
Journal:  J Biol Chem       Date:  2017-12-26       Impact factor: 5.157

3.  Fibromodulin suppresses nuclear factor-kappaB activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis.

Authors:  Yong-Hun Lee; William P Schiemann
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

4.  Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation.

Authors:  Shelly M Wuerzberger-Davis; Yuhong Chen; David T Yang; Jeffrey D Kearns; Paul W Bates; Candace Lynch; Nicholas C Ladell; Mei Yu; Andrew Podd; Hu Zeng; Tony T Huang; Renren Wen; Alexander Hoffmann; Demin Wang; Shigeki Miyamoto
Journal:  Immunity       Date:  2011-02-17       Impact factor: 31.745

5.  Vitamin D receptor absence does not enhance intestinal tumorigenesis in ApcPirc/+rats.

Authors:  Amy A Irving; Bayley J Waters; Jeremy R Seeman; Lori A Plum; Hector F DeLuca
Journal:  Biol Open       Date:  2022-07-06       Impact factor: 2.643

6.  Systemic autoimmunity in BAFF-R-mutant A/WySnJ strain mice.

Authors:  Christopher G Mayne; Ian J Amanna; Faye E Nashold; Colleen E Hayes
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

7.  Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Authors:  Stephanie Markovina; Natalie S Callander; Shelby L O'Connor; Jihoon Kim; Jae E Werndli; Martha Raschko; Catherine P Leith; Brad S Kahl; Kyungmann Kim; Shigeki Miyamoto
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

8.  Altered BAFF-receptor signaling and additional modifier loci contribute to systemic autoimmunity in A/WySnJ mice.

Authors:  Christopher G Mayne; Faye E Nashold; Yoshiteru Sasaki; Colleen E Hayes
Journal:  Eur J Immunol       Date:  2009-02       Impact factor: 5.532

9.  Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Authors:  Stephanie Markovina; Natalie S Callander; Shelby L O'Connor; Guangwu Xu; Yufang Shi; Catherine P Leith; KyungMann Kim; Parul Trivedi; Jaehyup Kim; Peiman Hematti; Shigeki Miyamoto
Journal:  Mol Cancer       Date:  2010-07-06       Impact factor: 27.401

10.  RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo.

Authors:  Wenzhi Tian; Hsiou-Chi Liou
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.